Pluvicto Radiopharmaceutical Therapy for Prostate Cancer

Pluvicto is a radiopharmaceutical medication designed to deliver targeted radiation to prostate cancer cells that express PSMA (prostate-specific membrane antigen). It is FDA-approved for treating metastatic castration-resistant prostate cancer (mCRPC) in men who have received only one androgen receptor pathway inhibitor.

This condition develops when prostate cancer cells spread beyond the prostate and resist hormone-based treatments. Pluvicto works by locating these cells and emitting low-level radiation to disrupt their function.

It may be recommended for patients with PSMA-positive mCRPC after only 1 androgen receptor pathway inhibitor.

Pluvicto delivers focused radiation directly to cancer cells, which means it minimizes damage to healthy tissues. Patients may experience a decline in PSA levels and a delay in disease progression.

Benefits of Pluvicto include:

• Targets PSMA-positive cancer cells
• Minimizes harm to healthy tissues
• Delays disease progression
• May improve symptoms and quality of life

Patients may experience nausea, fatigue, decreased appetite, dry mouth, or lowered blood counts. Our team closely monitors for these effects and offers support as needed.

You'll undergo PSMA imaging to confirm eligibility. On treatment days, plan to stay well-hydrated and follow your care team’s specific instructions.

Pluvicto is administered intravenously in an outpatient setting. Each treatment session lasts about 90 minutes, and patients typically undergo up to six sessions, spaced six weeks apart.

Radiation from the drug remains in your system for a short time. You’ll receive safety instructions and return for follow-up lab work and imaging.

Most patients resume normal activities shortly after treatment. Ongoing check-ins ensure that recovery is on track and any side effects are addressed early.